Pascal and Francis Bibliographic Databases

Help

Search results

Your search

au.\*:("ROSEN, Steven T")

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 83

  • Page / 4
Export

Selection :

  • and

Conceptual aspects of combining rituximab and Campath-IH in the treatment of chronic lymphocytic leukemiaNABHAN, Chadi; ROSEN, Steven T.Seminars in oncology. 2002, Vol 29, Num 1, pp 75-80, issn 0093-7754, SUP2Article

Recent advances and future directions using monoclonal antibodies for B-cell malignanciesROSEN, Steven T.Seminars in oncology. 1999, Vol 26, Num 5, issn 0093-7754, 125 p., SUP14Conference Proceedings

Current and ongoing clinical development of immunotherapy in B-cell malignanciesROSEN, Steven T.Seminars in oncology. 2002, Vol 29, Num 1, issn 0093-7754, 123 p., SUP2Serial Issue

Proceedings of the Northwestern University Medical School. Second Annual Oncology Consensus Conference: Recent Advances and New Therapeutic Directions for Hematologic MalignanciesROSEN, Steven T.Seminars in oncology. 2000, Vol 27, Num 6, issn 0093-7754, 111 p., SUP12Conference Proceedings

Treatment of aggressive non-Hodgkin's lymphomaCOIFFIER, B.Seminars in oncology. 1999, Vol 26, Num 5, pp 12-20, issn 0093-7754, SUP14Conference Paper

Chronic Lymphocytic Leukemia: A Clinical ReviewNABHAN, Chadi; ROSEN, Steven T.JAMA, the journal of the American Medical Association. 2014, Vol 312, Num 21, pp 2265-2276, issn 0098-7484, 12 p.Article

Rituximab in the treatment of diffuse large B-cell lymphomasCOIFFIER, Bertrand.Seminars in oncology. 2002, Vol 29, Num 1, pp 30-35, issn 0093-7754, SUP2Article

Chemotherapy sensitization by rituximab : Experimental and clinical evidenceWILSON, Wyndham H.Seminars in oncology. 2000, Vol 27, Num 6, pp 30-36, issn 0093-7754, SUP12Conference Paper

CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphomaCZUCZMAN, M. S.Seminars in oncology. 1999, Vol 26, Num 5, pp 88-96, issn 0093-7754, SUP14Conference Paper

Radiolabeled antibody therapy of B-cell lymphomasPRESS, O. W.Seminars in oncology. 1999, Vol 26, Num 5, pp 58-65, issn 0093-7754, SUP14Conference Paper

Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma : Interim follow-up of a multicenter phase ii trialHAINSWORTH, John D.Seminars in oncology. 2002, Vol 29, Num 1, pp 25-29, issn 0093-7754, SUP2Article

Advances in classification and therapy of indolent B-cell malignanciesKIPPS, Thomas J.Seminars in oncology. 2002, Vol 29, Num 1, pp 98-104, issn 0093-7754, SUP2Article

High-dose rituximab therapy in chronic lymphocytic leukemiaKEATING, Michael; O'BRIEN, Susan.Seminars in oncology. 2000, Vol 27, Num 6, pp 86-90, issn 0093-7754, SUP12Conference Paper

The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphomaWITZIG, Thomas E.Seminars in oncology. 2000, Vol 27, Num 6, pp 74-78, issn 0093-7754, SUP12Conference Paper

Overview of posttransplant B-cell lymphoproliferative disordersSWINNEN, L. J.Seminars in oncology. 1999, Vol 26, Num 5, pp 21-25, issn 0093-7754, SUP14Conference Paper

Overview of idiopathic thrombocytopenic purpura : New approach to refractory patientsBUSSEL, James B.Seminars in oncology. 2000, Vol 27, Num 6, pp 91-98, issn 0093-7754, SUP12Conference Paper

Rituximab : An insider's historical perspectiveGRILLO-LOPEZ, Antonio J.Seminars in oncology. 2000, Vol 27, Num 6, pp 9-16, issn 0093-7754, SUP12Conference Paper

Rituximab as first-line systemic therapy for patients with low-grade lymphomaHAINSWORTH, John D.Seminars in oncology. 2000, Vol 27, Num 6, pp 25-29, issn 0093-7754, SUP12Conference Paper

Current treatment of follicular low-grade lymphomasPETERSON, B. A.Seminars in oncology. 1999, Vol 26, Num 5, pp 2-11, issn 0093-7754, SUP14Conference Paper

Quality of life and treatment value in the management of hematologic malignanciesCELLA, D; WEBSTER, K. A.Seminars in oncology. 1999, Vol 26, Num 5, pp 34-42, issn 0093-7754, SUP14Conference Paper

The role of CAMPATH-I antibodies in the treatment of lymphoid malignanciesDYER, M. J. S.Seminars in oncology. 1999, Vol 26, Num 5, pp 52-57, issn 0093-7754, SUP14Conference Paper

The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapiesBALAGULA, Yevgeniy; ROSEN, Steven T; LACOUTURE, Mario E et al.Journal of the American Academy of Dermatology. 2011, Vol 65, Num 3, pp 624-635, issn 0190-9622, 12 p.Article

Current therapeutic paradigm for the treatment of non-Hodgkin's lymphomaFISHER, Richard I.Seminars in oncology. 2000, Vol 27, Num 6, pp 2-8, issn 0093-7754, SUP12Conference Paper

Principles of radioimmunotherapy for hematologists and oncologistsPRESS, Oliver W; RASEY, Janet.Seminars in oncology. 2000, Vol 27, Num 6, pp 62-73, issn 0093-7754, SUP12Conference Paper

Monoclonal antibody therapy of cancerWEINER, L. M.Seminars in oncology. 1999, Vol 26, Num 5, pp 43-51, issn 0093-7754, SUP14Conference Paper

  • Page / 4